Unibest

Pharmaceutical intermediates

Futibatinib Intermediates

3 pharmaceutical intermediates for Futibatinib. Indication: Cholangiocellular Carcinoma; Cholangiocarcinoma.

提交项目All intermediates

About Futibatinib

Originator
Taiho Pharmaceutical Co., Ltd.
Indication
Cholangiocellular Carcinoma; Cholangiocarcinoma
Approved Date
09/30/2022
NCE Patent
09/30/2027
DS/DP
02/23/2033

Available intermediates

3 intermediates currently listed for Futibatinib. Request specifications, documentation or a quotation for any item below.

Futibatinib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine151266-23-8//
(S)-tert-butyl 3-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidine-1-carboxylate1448171-01-4//
ethynyl-3,5-dimethoxybenzene171290-52-1//

Other programs under F

FebuxostatFexuprazan HClFezolinetantFilgotinib MaleateFinerenoneFluralanerFostamatinib disodium hexahydrateFruquintinib

Building toward Futibatinib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →